1.Rizvi, S. and G. J. Gores, Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology, 2013. 145(6): p. 1215–29.
2.Razumilava, N. and G. J. Gores, Cholangiocarcinoma. Lancet, 2014. 383(9935): p. 2168–79.
3.Doherty, B., V. E. Nambudiri, and W. C. Palmer, Update on the Diagnosis and Treatment of Cholangiocarcinoma. Curr Gastroenterol Rep, 2017. 19(1): p. 2.
4.Brito, A. F., et al., Cholangiocarcinoma: from molecular biology to treatment. Med Oncol, 2015. 32(11): p. 245.
5.Tseng, C. H., Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan. Gynecol Oncol, 2015.
6.Evans, J. M. M., et al., Metformin and reduced risk of cancer in diabetic patients. British Medical Journal, 2005. 330(7503): p. 1304–1305.
7.DeCensi, A., et al., Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis. Cancer Prevention Research, 2010. 3(11): p. 1451–1461.
8.Zhang, Z. J., et al., Reduced Risk of Lung Cancer With Metformin Therapy in Diabetic Patients: A Systematic Review and Meta-Analysis. American Journal of Epidemiology, 2014. 180(1): p. 11–14.
9.Schuler, K. M., et al., Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. Cancer Medicine, 2015. 4(2): p. 161–173.
10.Alimova, I. N., et al., Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle, 2009. 8(6): p. 909–915.
11.Ling, S., et al., Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines. Oncol Rep, 2014. 31(6): p. 2611–8.
12.Saengboonmee, C., et al., Metformin Exerts Antiproliferative and Anti-metastatic Effects Against Cholangiocarcinoma Cells by Targeting STAT3 and NF-kB. Anticancer Res, 2017. 37(1): p. 115–123.
13.Jiang, X. M., et al., Metformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma. Oncotarget, 2015. 6(5): p. 3178–3194.
14.Lord, S. R., et al., Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer. Cell metabolism, 2018. 28(5).
15.Wheaton, W. W., et al., Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife, 2014. 3: p. e02242.
16.Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells.
17.Shi, W. Y., et al., Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis, 2012. 3: p. e275.
18.Zakikhani, M., et al., Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res, 2006. 66(21): p. 10269–73.
19.Zhang, C. S., et al., Metformin Activates AMPK through the Lysosomal Pathway. Cell Metab, 2016. 24(4): p. 521–522.
20.Gwinn, D. M., et al., AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell, 2008. 30(2): p. 214–26.
21.Wu, L., et al., An Ancient, Unified Mechanism for Metformin Growth Inhibition in C. elegans and Cancer. Cell, 2016. 167(7): p. 1705–1718.e13.
22.Morvan, D., Functional metabolomics uncovers metabolic alterations associated to severe oxidative stress in MCF7 breast cancer cells exposed to ascididemin. Mar Drugs, 2013. 11(10): p. 3846–60.
23.Liu, X., et al., LC-based targeted metabolomics analysis of nucleotides and identification of biomarkers associated with chemotherapeutic drugs in cultured cell models. Anticancer Drugs, 2014. 25(6): p. 690–703.
24.Li, Y., et al., The antitumor effect of formosanin C on HepG2 cell as revealed by 1H-NMR based metabolic profiling. Chem Biol Interact, 2014. 220: p. 193–9.
25.Knuth, A., et al., Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J Hepatol, 1985. 1(6): p. 579–96.
26.Xia, J. and D. S. Wishart, MSEA: a web-based tool to identify biologically meaningful patterns in quantitative metabolomic data. Nucleic Acids Res, 2010. 38(Web Server issue): p. W71–7.
27.Chaiteerakij, R., et al., Risk Factors for Intrahepatic Cholangiocarcinoma: Association Between Metformin Use and Reduced Cancer Risk. Hepatology, 2013. 57(2): p. 648–655.
28.Shu, Y., et al., Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. The Journal of Clinical Investigation, 2007. 117(5): p. 1422–1431.
29.Sciacovelli, M., et al., The metabolic alterations of cancer cells. Methods Enzymol, 2014. 542: p. 1–23.
30.Cuyas, E., et al., Metformin targets histone acetylation in cancer-prone epithelial cells. Cell cycle (Georgetown, Tex.), 2016. 15(24): p. 3355–3361.
31.Pryor, R. and F. Cabreiro, Repurposing metformin: an old drug with new tricks in its binding pockets. The Biochemical journal, 2015. 471(3): p. 307–22.
32.Griss, T., et al., Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis. Plos Biology, 2015. 13(12).
33.Stephenne, X., et al., Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia, 2011. 54(12): p. 3101–10.
34.Meng, S., et al., Metformin activates AMP-activated protein kinase by promoting formation of the alphabetagamma heterotrimeric complex. J Biol Chem, 2015. 290(6): p. 3793–802.
35.Tsun, Z. Y. and R. Possemato, Amino acid management in cancer. Semin Cell Dev Biol, 2015. 43: p. 22–32.
36.Li, Z. and H. Zhang, Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression. Cellular and Molecular Life Sciences, 2016. 73(2): p. 377–392.
37.Lambert, I. H., et al., Physiological role of taurine—from organism to organelle. Acta Physiol (Oxf), 2015. 213(1): p. 191–212.
38.Aly, H. A. A. and R. M. Khafagy, Taurine reverses endosulfan-induced oxidative stress and apoptosis in adult rat testis. Food and Chemical Toxicology, 2014. 64(Supplement C): p. 1–9.
39.Hutson, S. M., A. J. Sweatt, and K. F. Lanoue, Branched-chain amino acid metabolism: implications for establishing safe intakes. J Nutr, 2005. 135(6 Suppl): p. 1557s–64s.
40.Melendez, A., et al., Autophagy genes are essential for dauer development and life-span extension in C. elegans. Science, 2003. 301(5638): p. 1387–91.
41.Madeo, F., et al., Caloric restriction mimetics: towards a molecular definition. Nat Rev Drug Discov, 2014. 13(10): p. 727–40.
42.Queiroz, E. A., et al., Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF–7 breast cancer cells. PLoS One, 2014. 9(5): p. e98207.
43.Cai, X., et al., Metformin Induced AMPK Activation, G0/G1 Phase Cell Cycle Arrest and the Inhibition of Growth of Esophageal Squamous Cell Carcinomas In Vitro and In Vivo. PLoS One, 2015. 10(7): p. e0133349.
44.Jeong, Y. K., et al., Metformin Radiosensitizes p53-Deficient Colorectal Cancer Cells through Induction of G2/M Arrest and Inhibition of DNA Repair Proteins. PLoS One, 2015. 10(11): p. e0143596.
45.Mkhikian, H., et al., Golgi self-correction generates bioequivalent glycans to preserve cellular homeostasis. eLife, 2016. 5: p. e14814.
46.Dennis, J. W., I. R. Nabi, and M. Demetriou, Metabolism, Cell Surface Organization, and Disease. Cell, 2009. 139(7): p. 1229–1241.
47.Lau, K. S., et al., Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell, 2007. 129(1): p. 123–34.